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Abstract We present the case of a 46-year old patient with Child-Pugh class C cirrhosis with 
MEDL-Score 16, and hepatocellular carcinoma invading the inferior vena cava and the 
right atrium. The etiology of cirrhosis is type 1 hereditary hemochromatosis with positive 
HFE C282Y/C282Y and H63D/H63D mutations. A systematic review of the literature 
was performed and only 30 cases of hepatocellular carcinoma with tumor thrombosis 
extending into the right atrium have been described. To our knowledge, this is the first 
case that evidences the presence in hereditary hemochromatosis of hepatocellular 
carcinoma with atypical invasion into the right atrium. Screening of patients with a 
family history of hereditary hemochromatosis allows detection of the disease in the 
asymptomatic phase, allowing initiation of early therapy and improved prognosis.   
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Highlights ✓ Hepatocellular carcinoma with right atrium invasion is a rare condition, especially in 
hereditary hemochromatosis. 
✓ All first-degree relatives of a patient diagnosed with type 1 hereditary hemochromatosis 
should be genetically tested for HFE mutations and monitored in order to prevent iron 
overload. 
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Introduction 
Vascular invasion into the portal vein (PV) occurs 
most frequently in hepatocellular carcinoma (HCC) (1, 
2). Inferior vena cava (IVC) invasion is rarely found in 
medical practice and is associated with a poorer 
prognosis (3). 
Hereditary hemochromatosis (HH) is a genetic 
disease with an autosomal recessive pattern of 
inheritance. Mutations in the genes encoding the 
proteins involved in iron metabolism induce increased 
intestinal absorption of iron and its excessive deposition 
in organs, causing their malfunction. The most frequent 
HFE gene mutations in type 1 HH are C282Y and H63D. 
The majority of patients are homozygous for the C282Y 
mutation or compound heterozygous C282Y/H63D (4). 
 In HH, there is a 20-fold higher risk for developing 
HCC compared to the general population. HCC occurs 
in about 10% of patients with HH (5), with half of the 
patients with HH dying from HCC (6). Ye et al. 
demonstrated that HFE C282Y may increase the odds of 
developing HCC, while HFE H63D is more likely 
associated with susceptibility to HCC without cirrhosis 
in the African population (7). 
 
Case report 
We report the case of a 46-year-old man who 
presented for the first time to a medical service for 
scleral jaundice, low protein leg edema, and increased 
abdominal volume due to ascites. Under drug treatment 
with diuretics and albumin supplements, edematous 
syndrome remitted in three weeks, but low-intensity 
pain occurred in the right hypochondrium associated 
with asthenia, fatigue, weight loss of about three kilos 
over the last month, and polyarthralgia. 
The patient reported a mean alcohol consumption 
of 50 g/day over the past three years, under the threshold 
of hepatotoxicity. The patient’s family history 
evidenced that two brothers (38 and 42-year-old) and an 
aunt (51-year-old) had died from cirrhosis at young 
ages. 
The physical exam revealed generalized skin 
hyperpigmentation; scleral jaundice; hippocratic fingers 
and toes; bilateral leg edema; bilateral diminished 
pectoral sound, sonority alternating with sub-dullness, 
bilateral diminished vesicular murmur; distended 
abdomen due to ascites, umbilical scar protrusion, and 
the presence of cavo-cave collateral circulation. 
Abdominal ultrasound detected a liver reduced in 
size, with irregular outline and a highly inhomogeneous 
structure, with inhomogeneous, confluent echogenic 
nodular masses having a maximum diameter of 83mm, 
in segment VII, suggestive of multicentric HCC. 
Doppler examination detected right suprahepatic vein 
and IVC thrombosis. The PV had a maximum diameter 
of 15 mm and blood flow was hepatoportal. The spleen 
was increased in volume (longitudinal axis length of 
174mm) and homogeneous in structure. The splenic 
vein had a maximum diameter of 13mm. A large amount 
of ascites was evidenced at the first examination and 
disappeared after treatment. Contrast-enhanced 
thoracoabdominal CT revealed a liver reduced in size, 
with irregular outline and a highly inhomogeneous 
structure, with multiple hypodense, high-uptake masses 
in the arterial phase with newly formed vessels from the 
hepatic artery, the largest mass being 78mm in size, in 
segments VI-VII (Figure 1). The tumor invaded the right 
hepatic vein, with extension of the tumor thrombus into 
the IVC, RA, and the segmental branches of the right PV 
(Figure 2); interaortocaval, retrocaval, celiac, and 
hepatic hilar adenopathies, as well as multiple bilateral 
pulmonary nodular lesions up to 3cm in size having a 
computed tomographic appearance typical of metastasis 
(Figure 3).  
 
Figure 1. Computed tomography, transverse 
section showing tumor behavior in the native, 
arterial and venous phase. 
 
Figure 2. Computed tomography, tumor 
thrombus extension to the right hepatic vein (A), 
inferior vena cava (B-axial, C-coronal), up to the 
right atrium, which it occupies entirely (D). 
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Figure 3. Computed tomography, 3D MIP 
reconstruction, 59.2 mm thickness, coronal 
section showing multiple lung metastases. 
Blood tests showed hypersplenism with 
pancytopenia, macrocytosis, cholestatic syndrome 
(alkaline phosphatase=652 U/L, gamma-GT=84 U/L), 
mixed hyperbilirubinemia (total bilirubin=4.1 mg/dl, 
direct bilirubin=2 mg/dl), hepatic cytolysis syndrome 
(aspartate-aminotransferase=339 U/L, alanine-
aminotransferase=239 U/L), hepatic synthetic 
dysfunction with spontaneously prolonged INR (1.55), 
serum albumin and serum creatinine within normal 
limits (albumin=3 g/dl, creatinine = 0.9 mg/dl), and 
hypersideremia (205=μg/dl).   
The diagnosis of Child-Pugh class C cirrhosis with 
a MEDL-Score 16, HCC invading the right suprahepatic 
vein, IVC, RA and the right PV, lung and lymph node 
metastases was established. 
The viral etiology of chronic liver disease was 
excluded by negative HBs Ag and anti-HCV antibody. 
Given the patient’s family history, cirrhosis of uncertain 
etiology with alcohol consumption below the threshold 
of toxicity, hypersideremia, generalized melanoderma, 
and the sudden onset of liver cirrhosis at the stage of 
complications, assessing the etiology of cirrhosis in 
relation to hereditary causes, particularly HH, was 
considered necessary. 
The diagnosis of type 1 HH was confirmed by 
increased serum ferritin levels (1492 ng/ml) and 
transferrin saturation (85.61%), the patient being 
homozygous for both C282Y and H63D HFE mutations.  
For the characterization of the liver tumor mass, 
the following tumor markers were measured: alpha-
fetoprotein= 24.81 ng/ml (upper normal value: 9 ng/ml) 
and CA 19.9, which ranged within normal limits. Given 
the slightly increased level of alpha-fetoprotein, the 
diagnosis of HCC was confirmed by liver puncture 
biopsy (Figure 4). 
 
Figure 4. Hematoxylin-eosin stain showing 
hepatocellular carcinoma. 
Intracardiac tumor extension was evaluated by 
transthoracic echocardiography, which evidenced a 
polylobulated tumor mass 27/43 mm in size, occupying 
the entire RA and compressing the tricuspid annulus 
(Figure 5). No signs of heart failure were detected. 
 
Figure 5. Transthoracic echocardiography, 4-
chamber apical view, showing a 27/43 mm 
hyperechoic thrombus in the right atrium.  
On discharge, palliative therapy was recommended, 
which included low molecular weight heparin, tyrosine 
kinase inhibitors, hepatoprotective drugs, loop diuretics, 
and anti-aldosterone drugs. Etiological treatment with 
systematic phlebotomy and iron chelators was not 
initiated due to the presence of hypersplenism with 
pancytopenia and end-stage liver disease. Death from 
liver failure with grade IV hepatoportal encephalopathy 
occurred after 8 weeks. 
Screening of patients with a family history of HH 
allows for early initiation of specific therapy and 
improved prognosis. We recommended screening for 
the patient’s 8 living brothers and their 11 offspring.  So 
far, the patient’s son and 3 other brothers, aged 38, 42 
and 48 years, respectively, have been evaluated 
clinically, biologically, and genetically. Two brothers 
aged 42 and 48 years have cirrhosis evidenced by 
ultrasound. The 42-year-old brother has the 
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C282Y/C282Y HFE mutation, serum ferritin=1207 
ng/ml and transferrin saturation=76.57%, consequently 
a diagnosis of certainty of hemochromatosis. The 
recommended treatment consists of weekly phlebotomy 
and iron chelation therapy during the first 2 weeks. The 
two other brothers, aged 48 and 38 years respectively, 
are carriers of the C282Y/C282Y HFE mutation, and of 
the C282Y/H63D HFE mutation respectively. The 48 
year-old brother has serum ferritin=657 ng/ml and 
transferrin saturation=65%. He was recommended 
weekly phlebotomy. The 38 year-old brother with serum 
ferritin=254 ng/ml and transferrin saturation=37% will 
be evaluated annually in order to detect the optimal time 
for initiation of phlebotomy. The genetic testing of the 
patient’s son did not reveal HFE gene mutations (Figure 
6). 
 
  Figure 6. Genetic test results within patient’s family 
Discussion 
HCC cases with tumor thrombosis extending to the 
RA are extremely rare, only 30 cases have been 
described. None of these was documented in HH (3). 
Intracardiac thrombosis is associated with an increased 
risk of sudden death from pulmonary thromboembolism 
or acute heart failure, and more frequent and more 
extensive lung metastasis. Liver resection and surgical 
removal of the thrombus have proved to be the most 
effective approach in the case of patients with resectable 
liver tumors and sufficient residual hepatic reserve, with 
a mean survival of 19 months after surgery (8). In the 
case of our patient, multiple liver tumors, metastatic 
adenopathies, and secondary lung tumors 
contraindicated a curative or palliative surgical 
approach. 
Screening is an important component of preventive 
care. It consists of the identification of an asymptomatic 
disease, harmful condition, or risk factor, with the 
overall aim that the condition be caught early before it 
causes harm to the affected individual. Since HH is 
present at birth, its cause cannot be removed, and 
primary prevention is not practical. However, secondary 
prevention, which aims to detect early disease when it is 
asymptomatic and when treatment might stop its 
progression, is a viable option (9, 10). 
Screening is performed for all first-degree relatives 
of patients with HH and includes HFE genotyping and 
annual monitoring by determination of serum ferritin 
and transferrin saturation (TS). The ideal age to start HH 
screening is between 18 and 30 years, when signs of the 
disease caused by iron deposition in organs occur. 
Phlebotomy is initiated in the case of asymptomatic 
patients with a family history of HH who have a 
progressive increase in serum ferritin and transferrin 
saturation, as well as symptomatic patients, with severe 
organ damage. Phlebotomy is initiated at serum ferritin 
values >500 ng/ml (serum ferritin > 1000 ng/ml shows 
that the complications of excessive iron deposition are 
already present) and at a TS >50%. One phlebotomy 
session is conducted every 1-2 weeks, during which 500 
ml blood are removed. Phlebotomy is performed weekly 
until serum ferritin is <50 ng/ml and TS is <50%. This 
is followed by a maintenance period, during which 
phlebotomy is performed every 2-4 months so that the 
serum ferritin level is maintained between 50-100 
ng/ml. Iron chelators are preferred only when 
phlebotomy is contraindicated (severe/moderate 
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anemia), is not well tolerated (hemodynamic instability, 
post-procedural symptomatic hypovolemia), or is 
ineffective (aceruloplasminemia). Use of iron chelation 
has been suggested in conjunction with phlebotomy in 
patients with massive iron overload and organ damage, 
in which rapid removal of the iron burden may be 
required. 
 
Conclusions 
We presented the case of a young patient diagnosed 
with multicentric HHC at the metastatic stage, with 
tumor thrombosis extending to the RA, developed in 
cirrhosis of hereditary etiology, type 1 HH. Genetic 
counseling in HH is extremely important for early 
diagnosis of the affected offspring and initiation of 
monitoring and specific therapy in order to improve 
their prognosis. 
 
Abbreviations: HCC: hepatocellular carcinoma; 
HH: hereditary hemochromatosis; IVC: inferior vena 
cava; PV: portal vein; RA: right atrium; TS: transferrin 
saturation 
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